Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
August 2019—LGC Maine Standards released its Validate SP3 linearity and calibration verification kit for Roche Cobas and Beckman Coulter Immage analyzers. The kit, in a human serum matrix, evaluates α1-acid glycoprotein, antistreptolysin O, B2-microglobulin, and immunoglobulin E.
August 2019—Hamilton Company and Enable Biosciences announced a collaboration to provide fully automated processing of up to 96 liquid biopsy samples at one time using a novel ultra-sensitive and highly specific immunoassay in a hands-free workflow. The immunoassay, available for research applications in type 1 diabetes, Lyme disease, allergy, and HIV testing, is intended to support development of early-stage treatment interventions to improve patient health and quality of life with reduced disease-related complications.
August 2019—MDxHealth announced that a second clinical validation study demonstrating the performance of its liquid biopsy test SelectMDx for prostate cancer has been published in the Journal of Urology (Haese A, et al. 2019;202[2]:256–263).
August 2019—Loop Genomics has expanded its kits and services capabilities to provide researchers with ultra-high resolution microbiome sequencing solutions using long reads on Illumina sequencers. The four kits are a low biomass (e.g. human skin) phased V1–V9 full-length 16S kit with picogram input amounts and zero human DNA background, a phased 18S-ITS1-ITS2 long-read solution for ultra-high
August 2019—Thermo Fisher introduced its Invitrogen Collibri DNA Library Prep Kits for high-throughput Illumina systems. The kits contain a tracking dye to provide an in-process visual cue, which aims to improve workflow success.
August 2019—The FDA approved lenalidomide (Revlimid, Celgene Corp.) in combination with a rituximab product for previously treated follicular lymphoma and previously treated marginal zone lymphoma.
August 2019—Binding Site’s Immunologicals Group added two native tick-borne encephalitis viral antigens to its line of products for in vitro diagnostic manufacturing and research applications. The standard version of the antigen as well as the premium version are for use as components in enzyme immunoassay testing procedures.
August 2019—Oxford Gene Technology has expanded its SureSeq portfolio with the SureSeq NGS Library Preparation Kit, a library preparation solution for hybridization-based target capture in next-generation sequencing. The kit includes a ready-to-use hybridization and wash buffer. OGT has also developed a library preparation automation workflow available for the Agilent Bravo NGS (Option A) instrument that aims to further reduce manual handling and save time.
August 2019—Bühlmann Laboratories received FDA 510(k) clearance for its Bühlmann fCAL turbo in vitro diagnostic assay intended for the quantitative measurement of fecal calprotectin in human stool.
August 2019—BD announced the EU launch of its CE-IVD-marked BD COR, an automated, high-throughput molecular diagnostics system developed for large-capacity laboratories.
